Development and commercialization of radiopharmaceutical products for the diagnosis and treatment of cancer, with a focus on large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as rare and orphan cancer indications, such as neuroblastoma.
Development of SARTATE™, a radiopharmaceutical theranostic for the diagnosis and treatment of neuroblastoma. SARTATE™ is currently in a Phase 3 clinical trial for the treatment of neuroblastoma.
Development of SAR-bisPSMA, a radiopharmaceutical theranostic for the diagnosis and treatment of prostate cancer. SAR-bisPSMA is currently in a Phase 2 clinical trial for the treatment of prostate cancer.
Development of SAR-Bombesin, a radiopharmaceutical theranostic for the diagnosis and treatment of neuroendocrine tumours (NETs). SAR-Bombesin is currently in a Phase 2 clinical trial for the treatment of NETs.
Delivery of radiopharmaceutical products to patients as quickly as possible to make a significant impact on the lives of cancer patients and their families.
Commitment to developing and commercialising innovative radiopharmaceutical products that improve the diagnosis and treatment of cancer.
